2022-RA-909-ESGO AGO-OVAR 28/ENGOT-ov57: niraparib vs niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer (a multicentre randomised phase III trial)

Florian Heitz; Christian Marth; Stéphanie Henry; Alexander Reuss; David Cibula; Lydia Gaba; Nicoletta Colombo; Sandra Polleis; Philipp Harter

doi:10.1136/ijgc-2022-ESGO.590

Citation Tools

Ovarian cancer

2022-RA-909-ESGO AGO-OVAR 28/ENGOT-ov57: niraparib vs niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer (a multicentre randomised phase III trial)

Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Heitz F, Marth C, Henry S, et al

2022-RA-909-ESGO AGO-OVAR 28/ENGOT-ov57: niraparib vs niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer (a multicentre randomised phase III trial)

International Journal of Gynecologic Cancer 2022;32:A277.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password